1. Townsend CW, The haemorrhagic disease of the
newborn. Arch Paediatr. 1894;11:559-565.
2. Dam H, Schønheyder F. The occurrence
and chemical nature of vitamin K. Biochem J. 1936;5:897-890
3. McNinch A, Busfield A, Tripp J. Vitamin K deficiency bleeding in
Great Britain and Ireland: British paediatric surveillance unit surveys,
1993-94 and 2001-02.
Arch Dis Child. 2007;92:759-766.
[PubMed: 17537761]
4. Fregin A, Rost S, Wolz W, Krebsova A, Muller CR, Oldenburg
J. Homozygosity mapping of a second gene locus for hereditary
combined deficiency of vitamin K-dependent clotting factors to the centromeric
region of chromosome 16. Blood. 2002;100:3229-3232.
5. Hubbard D, Tobias JD. Intracerebral hemorrhage
due to hemorrhagic disease of the newborn and failure to administer
vitamin K at birth. South Med J. 2006;99:1216-1220.
6. Sutor AH, von Kries R, Cornelissen EAM, McNinch AW, Andrew
M. Vitamin K deficiency bleeding (VKDB) in infancy.
Thromb
Haemost. 1999;81:456-461.
[PubMed: 10102477]
7. Golding J, Greenwood R, Birmingham K, Mott M. Childhood
cancer, intramuscular vitamin K, and pethidine given during labour. BMJ.
1992;305:341-346.
8. Roman E, Fear NT, Ansell P, et al. Vitamin K and
childhood cancer: analysis of individual patient data from six case-control
studies.Br J Cancer. 2002;86:63-69.
9. Sutor AH. New aspects of vitamin K prophylaxis.
Semin
Thromb Hemost. 2003;29:373-376.
[PubMed: 14517749]
10. Levi M, de Jonge E, van der Poll T, ten Cate H. Advances
in the understanding of the pathogenetic pathways of disseminated
intravascular coagulation result in more insight in the clinical
picture and better management strategies.
Semin Thromb Hemost. 2001;27:569-575.
[PubMed: 11740680]
11. Taylor FB Jr, Toh CH, Hoots WK, Wada
H, Levi M. Scientific Subcommittee on Disseminated
Intravascular Coagulation (DIC) of the International Society on
Thrombosis and Haemostasis (ISTH). Towards definition, clinical
and laboratory criteria, and a scoring system for disseminated intravascular
coagulation. Thromb Haemost. 2001;86:1327-1330.
12. Gross SJ, Filston HC, Anderson JC. Controlled
study of treatment for disseminated intravascular coagulation in
the neonate. J Pediatr. 1982;100:445-448.
13. Mueller MM, Bomke B, Seifried E. Fresh frozen plasma in patients
with disseminated intravascular coagulation or in patients with
liver diseases. Thromb Res. 2002;107:S9-17.
14. Levi M, de Jonge E, van der Poll T. New treatment strategies for
disseminated intravascular coagulation based on the current understanding
of the pathophysiology.
Ann Med. 2004;36:41-49.
[PubMed: 15000346]
15. Abraham E, Laterre PF, Garg R, et al. Administration
of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS)
Study Group. Drotrecogin alfa (activated) for adults with
severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332-1341.
16. Hanada T, Abe T, Takita H. Antithrombin III concentrates
for treatment of disseminated intravascular coagulation in children. Am
J Pediatr Hematol Oncol. 1985;7:3-8.
17. Nadel S, Goldstein B, Williams
MD, et al. Researching severe sepsis and organ dysfunction
in children: a global perspective (RESOLVE) study group. Lancet. 2007;369:836-843.
18. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation
disorders in liver disease.
Sem Thromb Hemost. 2002;22:83-96.
[PubMed: 11928081]
19. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb
Res. 1999;95(4 suppl 1):S13-17.
20. O’Connell KA, Wood JJ, Wise RP, Lozier JN,
Braun MM. Thromboembolic adverse events after use of recombinant
human coagulation factor VIIa. JAMA. 2006;295:293-298.
21. Taddio A, Brescia AC, Lepore L, Rose CD. Steady
improvement of prothrombin levels after cyclophosphamide therapy
in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS). Clin
Rheumatol. 2007;26:2167-2169.
22. Streiff MB, Ness PM. Acquired factor V inhibitors:
a needless iatrogenic complication of bovine
thrombin exposure.
Transfusion.
2002;42:18-26.
23. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology
and treatment. Hematology Am Soc Hematol Educ Program. 2006;432-437.
24. Franchini M, Lippi G. Acquired von Willebrand
syndrome: an update. Am J Hematol. 2007;82:368-375.
25. Salooja N, Martin P, Khair K, Liesner R, Hann I. Severe
factor V deficiency and neonatal intracranial haemorrhage: a case
report. Haemophilia. 2000;6:44-46.
26. González-Boullosa R, Ocampo-Martínez
R, Alarcón-Martín MJ, Suárez-Rodríguez
M, Domínguez-Viguera L, González-Fajo G. The
use of activated recombinant coagulation factor VII during haemarthroses
and synovectomy in a patient with congenital severe factor V deficiency. Haemophilia.
2005;11:167-70.
27. Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation
of an acquired coagulation factor V inhibitor with intravenous immune
globulin. J Pediatr Hematol Oncol. 1997;19:226-231.
28. Collins PW. Treatment of acquired hemophilia A.
J
Thromb Haemost. 2007;5:893-900.
[PubMed: 17461924]
29. Franchini M, Veneri D, Lippi G. The use of recombinant
activated factor VII in congenital and acquired von Willebrand disease. Blood
Coagul Fibrinolysis. 2006;17:615-619.